Ann: Appendix 4C - quarterly, page-110

Point 1 - take a look at their own governance document, they’ve failed to meet their own standard to appoint another female board member, we still don’t have the required number of Australian resident directors, our ‘non-exec’ chair can hardly be considered independent when he’s such a large shareholder and seems to sit on his own remuneration committee.

Point 2 - self evident, try reading ASIC/ASX obligations for listed entities we’ve been in breach for months

Point 3 - https://eganassociates.com.au/wp-content/uploads/2017/07/KMP-Report-July-2017.pdf

Point 4 - revenue expectations reiterated until moments before they were missed by a huge margin, interviews stating timeframes for events continually failing to eventuate (ref interviews)

Point 5 - yes this is opinion, yet we’re told that equity won’t be issued for capital and that debt can be obtained to fund business now runs are on the board, what experience does GR or the rest of the board have in guiding a growth phase American based chemicals company?

Point 6 - opinion again but you’d have to be slightly unhinged to disagree

So there you have it mainly fact, with a bit of logically based opinion.

Rather than bagging the carefully constructed positions of others perhaps you can explain why the current board and their remuneration have any justification in continuing unchecked?